Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
Campbell & CO Investment Adviser LLC Makes New $560,000 Investment in AnaptysBio, Inc. $ANAB
03:51am, Thursday, 22'nd Jan 2026
Campbell and CO Investment Adviser LLC bought a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchan
AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
11:25pm, Tuesday, 13'th Jan 2026
AnaptysBio, Inc. (ANAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally
06:18pm, Sunday, 11'th Jan 2026
An AnaptysBio director sold 3,900 shares of the stock on Dec. 23 for a total value of $193,342.50. The sale represented 28.82% of J.
What Investors Should Know About a $163K AnaptysBio Insider Sale
11:39am, Sunday, 11'th Jan 2026
The chief medical officer of AnaptysBio sold 3,650 shares for $163,191.50 on Thursday. The transaction represented 8.0% of Paul Lizzul's direct common stock holdings, reducing his direct stake from 45
Paul Lizzul Sells 3,650 Shares of AnaptysBio (NASDAQ:ANAB) Stock
05:20am, Sunday, 11'th Jan 2026
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Paul Lizzul sold 3,650 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $
Daniel Faga Sells 14,281 Shares of AnaptysBio (NASDAQ:ANAB) Stock
04:40am, Sunday, 11'th Jan 2026
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 14,281 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average pr
Eric Loumeau Sells 9,639 Shares of AnaptysBio (NASDAQ:ANAB) Stock
05:22am, Saturday, 10'th Jan 2026
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Eric Loumeau sold 9,639 shares of the business's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price
Daniel Faga Sells 9,202 Shares of AnaptysBio (NASDAQ:ANAB) Stock
05:22am, Saturday, 10'th Jan 2026
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) CEO Daniel Faga sold 9,202 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $45.11, fo
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
07:09pm, Thursday, 08'th Jan 2026
AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sa
Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
06:00pm, Thursday, 08'th Jan 2026
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
04:15pm, Tuesday, 06'th Jan 2026
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:32am, Monday, 22'nd Dec 2025
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve research firms that are covering the stock, MarketBeat.com reports. One research analys
Insider Selling: AnaptysBio (NASDAQ:ANAB) Insider Sells $460,000.00 in Stock
05:34am, Sunday, 21'st Dec 2025
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) insider Eric Loumeau sold 10,000 shares of the company's stock in a transaction on Wednesday, December 17th. The shares were sold at an average price
WASHINGTON , Dec. 15, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administ
Anaptys Announces Participation in December Investor Conferences
04:15pm, Tuesday, 25'th Nov 2025
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
